# Andrew X. Zhu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/andrew-x-zhu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 80,480 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 116 |
| i10-index | 342 |
| Last Known Institution | Johns Hopkins University |
| OpenAlex ID | https://openalex.org/A5088566246 |
| ORCID iD | https://orcid.org/0000-0003-4873-5033 |
| Works | 809 |

## Researcher papers

- [AASLD guidelines for the treatment of hepatocellular carcinoma](https://scholariq.org/papers/aasld-guidelines-for-the-treatment-of-hepatocellular-carcinoma/)
- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/)
- [Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment](https://scholariq.org/papers/intrahepatic-cholangiocarcinoma-an-international-multi-institutional-analysis-of/)
- [Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma](https://scholariq.org/papers/polyclonal-secondary-i-fgfr2-i-mutations-drive-acquired-resistance-to-fgfr/)
- [A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma](https://scholariq.org/papers/a-nomogram-to-predict-long-term-survival-after-resection-for-intrahepatic/)
- [Recurrence after operative management of intrahepatic cholangiocarcinoma](https://scholariq.org/papers/recurrence-after-operative-management-of-intrahepatic-cholangiocarcinoma/)
- [A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer](https://scholariq.org/papers/a-phase-ii-and-biomarker-study-of-ramucirumab-a-human-monoclonal-antibody/)
- [The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer](https://scholariq.org/papers/the-clinical-landscape-of-cell-free-dna-alterations-in-1671-patients-with/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Johns Hopkins University](https://scholariq.org/institutions/johns-hopkins-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.